6 results about "Immunosuppressive effect" patented technology

The present application relates to the application of open-cage borane compounds in the preparation of immunosuppressants, belonging to the technical field of biological medicine. The open-cage borane compounds of the present application include nest borane compounds and / or spider web borane compounds, and the pharmaceutically acceptable solvates or pharmaceutically acceptable complexes of the nest borane compounds and the spider web borane compounds. The open-cage boron clusters of the present application have dehydrogenase-like activity, can catalyze the dehydrogenation reaction of hydroxyl-containing organic substrates in a biological system, promote the conversion of NAD(P) + to NAD(P)H, further improve the intracellular oxidation-reduction ratio, induce cell redox stress, and further reshape the metabolic pattern of HSCs from the source, promote the differentiation of immune cells to immunosuppressive phenotype, and play an immunosuppressive role.

This invention discloses an engineered attenuated Salmonella VNP-SNase, its preparation method, and its applications, including methods and compositions for treating various solid tumors or metastatic tumors. Specifically, engineered attenuated Salmonella capable of expressing and secreting SNase is recruited to the tumor microenvironment through tumor targeting, specifically degrading intratumoral neutrophil extracellular traps (NETs), weakening the killing effect of NETs on Salmonella, increasing its intratumoral colonization, and simultaneously improving the tumor-promoting and immunosuppressive effects caused by NETs, ​​while effectively preventing bacteria from off-target into normal organs. By releasing SNase to activate / regulate the immune system and directly / indirectly inhibit tumors, it can act as an effective immune effector.

The present invention provides methods and materials for treating mammals (e.g., humans) that have or are at risk of developing a disease or condition characterized by tissue inflammation and / or degeneration. [Solution] For example, mesenchymal stem cells (MSCs) that express tissue-targeting antigen receptors (e.g., chimeric antigen receptors) capable of exerting immunosuppressive effects in targeted tissues are provided, as well as a method using such MSCs.

This invention discloses an engineered extracellular vesicle and its application in the preparation of products for treating autoimmune diseases. The engineered extracellular vesicle is either an IDO1-overexpressing engineered extracellular vesicle (MSC-IDO1-EVs) or a CSF1-overexpressing engineered extracellular vesicle (MSC-CSF1-EVs). The engineered extracellular vesicles provided by this invention exhibit significant immunosuppressive effects, reducing the secretion of inflammatory cytokines. In animal models, they effectively reduce proteinuria levels, significantly reduce blood dsDNA / ANA levels, effectively alleviate kidney damage caused by autoimmune diseases such as renal immune complex deposition, diffuse thickening of the glomerular basement membrane, and mesangial structural disorder, and reduce overall inflammation levels in mice. The therapeutic effect is significantly superior to that of unmodified MSC-EVs. The engineered extracellular vesicles provided by this invention significantly improve the therapeutic effect on autoimmune diseases.

This invention relates to compositions, and uses and methods thereof, with therapeutic deciparticles. Described herein are deciparticle (nanoparticle) compositions composed of an amphiphilic compound complexed with an auxiliary compound such as a biologically active molecule. Deciparticles of this invention are active drugs having potency for anti-tumor effects and for immunosuppression. This invention is also directed to amphiphilic compounds useful for making deciparticle complexes.

This invention relates to the field of biomedicine, specifically to an oncolytic virus targeting TIPE2, its preparation method, and its applications. This invention constructs a recombinant expression vector by inserting a TERTp fragment, a TIPE2 shRNA fragment, and a promoter driving the expression of the TIPE2 shRNA fragment into the vector. This achieves effective oncolytic function without affecting normal cell viability, and also effectively silences the expression of the TIPE2 gene in immunosuppressive cells, weakening the immunosuppressive effect in the tumor microenvironment, reshaping the body's anti-tumor immune response, and thus achieving a more effective tumor treatment effect.